A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.

The c-Met receptor tyrosine kinase is emerging as a novel target in many solid tumors, including lung cancer. PHA-665752 was identified as a small molecule, ATP competitive inhibitor of the catalytic activity of the c-Met kinase. Here, we show that treatment with PHA665752 reduced NCI-H69 (small cell lung cancer) and NCI-H441 (non-small cell lung cancer) tumorigenicity in mouse xenografts by 99% and 75%, respectively. Reduction in tumor size was also observed by magnetic resonance imaging of tumors in mice. PHA665752 inhibited c-Met phosphorylation at the autophosphorylation and c-Cbl binding sites in mouse xenografts derived from non-small cell lung cancer cell lines (NCI-H441 and A549) and small cell lung cancer cell line (NCI-H69). PHA665752 also inhibited angiogenesis by >85% in all the abovementioned cell lines and caused an angiogenic switch which resulted in a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These studies show the feasibility of selectively targeting c-Met with ATP competitive small molecule inhibitors and suggest that PHA665752 may provide a novel therapeutic approach to lung cancer.

[1]  T. Pawson,et al.  Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.

[2]  David I. Smith,et al.  A role for common fragile site induction in amplification of human oncogenes. , 2002, Cancer cell.

[3]  G. V. Vande Woude,et al.  Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. , 1996, Oncogene.

[4]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[6]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[7]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[8]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[9]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[10]  T. Nakamura,et al.  Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. , 1994, Oncogene.

[11]  Lothar Hennighausen,et al.  Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways , 2003, Oncogene.

[12]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[13]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[14]  W. Hung,et al.  Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. , 2003, Cancer research.

[15]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[16]  T. Pawson,et al.  The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Stamos,et al.  The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.

[18]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Schemper,et al.  Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. , 1990, Cancer research.

[20]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.